Figure 3.
Long-term outcomes after JCAR021 CD19 CAR T-cell therapy. Kaplan-Meier estimates for (A) OS; (B) RFS; (C) DOR; and (D) cumulative incidence of relapse in CR/CRi patients after JCAR021 with death and allo-HCT as competing events, landmarked at day +28.

Long-term outcomes after JCAR021 CD19 CAR T-cell therapy. Kaplan-Meier estimates for (A) OS; (B) RFS; (C) DOR; and (D) cumulative incidence of relapse in CR/CRi patients after JCAR021 with death and allo-HCT as competing events, landmarked at day +28.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal